Por: The New York Times Health March 08, 2023
The company that makes Makena, the only drug aimed at preventing preterm birth, announced on Tuesday that it was voluntarily pulling the medication off the market after advisers for the Food and Drug Administration concluded that the treatment did not help pregnant women at all.Makena’s drugmaker, the Covis Pharma Group, said its had been made in deference to a F.D.A. advisory committee that agreed unanimously in October that a large study had... + full article
The New York Times USA Health March 02, 2023
Elizabeth Decker had a stressful second pregnancy, plagued by daily vomiting and the worry that this baby, like her first, would drive her blood pressure dangerously high and need to be delivered preterm. Oddly, the most relaxing part was her final trimester, which overlapped... + más
Home Births Rose During the Pandemic, Study Shows | Time
US births increased in 2021 for 1st time in 7 years: CDC | ABC News
CNN USA Health November 15, 2022
CNN — The rate of premature birth in the United States is climbing, according to the infant and maternal health nonprofit March of Dimes. On Tuesday, the organization released its , which involves a newly updated calculation system. Taking an in-depth look at premature... + más
FDA panel recommends pulling preterm birth drug from the market | The Boston Globe
F.D.A. Panel Recommends Pulling Preterm Birth Drug From the Market | The New York Times
Time USA Life October 28, 2022
Every day, as I rush to preterm deliveries on the labor floor of my safety-net hospital and work beside incubators and clear plastic hospital bassinets, one of my patients’ mothers confides to me her belief that if she had only done that one thing differently during pregnancy,... + más
US gets D+ grade for rising preterm birth rates, new report finds | CNN
The New York Times USA Health October 20, 2022
A Food and Drug Administration advisory committee on Wednesday recommended removing the drug Makena from the market, after years of study showed the fast-tracked drug had failed to prevent preterm births.Makena has been in use for 11 years, and the panel’s vote was widely of... + más
FDA panel recommends revoking the approval of controversial drug intended to prevent premature birth | CNBC
The Boston Globe USA Nation October 20, 2022
A Food and Drug Administration advisory committee on Wednesday recommended removing the drug Makena from the market, after years of study showed the fast-tracked drug had failed to prevent preterm birth.Makena has been in use for 11 years, and the panel’s vote was widely... + más
Los Angeles Times USA Science October 20, 2022
A federal advisory panel voted Wednesday to recommend that the only approved drug to prevent premature birth be removed from pharmacy shelves because studies have shown it does not work. The 14-to-1 vote came more than a decade after the Food and Drug Administration approved the... + más
FDA panel backs removal of unproven pregnancy drug | Portland Press Herald
CNBC USA Health October 19, 2022
An advisory panel to the Food and Drug Administration voted Wednesday to take a drug intended to prevent premature births off the market, saying that it remains doubtful that the drug works.The recommendation, in a 14-1 vote, from the agency's Obstetrics, Reproductive and... + más
FDA panel backs removal of unproven pregnancy drug | WPLG Local 10
ALS drug wins FDA approval despite questionable data | ABC News
About iurex | Privacy Policy | Disclaimer |